VACV WR148 Specific Neutra™ Antibody Products

Are you encountering difficulties in advancing vaccine development, conducting viral research, or deciphering immune responses to poxvirus infections? Creative Biolabs' VACV WR148 Specific Neutra™ Antibody Products help you achieve accurate and reliable results in your research by providing high-quality antibodies. Our advanced antibody development platform and rigorous validation processes ensure that our products meet the needs of researchers working with Vaccinia Virus.

Overview of VACV WR148

Vaccinia virus (VACV), a member of the Orthopoxvirus genus, encodes a large, double-stranded DNA genome and remains historically pivotal as the live-vaccine strain instrumental in the global eradication of smallpox. Notably, the WR148 protein—a strain-specific virulence factor encoded by the Western Reserve (WR) strain—emerges as a critical mediator of viral-host immune interplay, though its mechanistic contributions to pathogenesis remain incompletely resolved. Current evidence suggests WR148's structural complexity, potentially involving conformational flexibility or conserved hydrophobic domains, may underpin its role in immune evasion. For instance, it is plausible that WR148 interacts with host signaling intermediates, such as interferon response elements or NF-κB regulators, to subvert antiviral defenses.

Related Signaling Pathways

VACV engages host cellular signaling networks through mechanisms that subvert immune surveillance and promote viral propagation. While WR148's precise role in these interactions remains under investigation, preliminary evidence suggests its potential involvement in three key axes: interferon (IFN) signaling, NF-κB activation, and apoptotic regulation. Such multifunctional hijacking of host machinery could illuminate WR148's broader role in immune evasion and pathogenesis.

Fig. 1 Detection signaling pathway of viral DNA and its counteraction by VACV.¹

Application of Anti-VACV WR148 Antibody

Vaccine Efficacy Studies

Anti-VACV WR148 antibodies are pivotal for evaluating next-generation smallpox vaccines. Quantifying these antibodies in vaccinated hosts gauges immune response strength, while neutralization assays reveal their capacity to block viral infectivity—a critical correlate of protection. Epitope mapping using such antibodies identifies protective antigens, informing vaccine optimization. Creative Biolabs' VACV WR148-Specific Neutra™ Antibodies, rigorously validated, standardize these assessments, minimizing experimental variability. This precision aids in distinguishing robust, durable immunity from transient responses, accelerating translational vaccine development. Integrating these tools with functional serology could refine correlates of immunity, advancing both mechanistic understanding and clinical vaccine design.

Viral Pathogenesis Research

Anti-VACV WR148 antibodies are indispensable for probing viral pathogenesis, enabling precise monitoring of WR148's spatiotemporal expression and subcellular localization during infection. Such spatial-temporal profiling delineates its functional contributions to viral replication cycles. Immunofluorescence assays, for instance, leverage these antibodies to map WR148's distribution in infected tissues via confocal microscopy, revealing compartment-specific trafficking patterns. Furthermore, IP-MS identifies WR148's interactome—host or viral binding partners postulated to form multiprotein complexes critical for immune evasion.

Creative Biolabs is committed to delivering superior antibody products and services to meet our customers' research requirements. Our VACV WR148 Specific Neutra™ Antibody Products are designed with confirmed technology, subjected to stringent validation. Our products guarantee specificity, sensitivity, and consistent performance.

REFERENCE

1. El-Jesr, Misbah, Muad Teir, and Carlos Maluquer de Motes. "Vaccinia virus activation and antagonism of cytosolic DNA sensing." Frontiers in Immunology 11 (2020): 568412. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2020.568412